| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -13,733 |
| Stock-based compensation expense | 1,850 |
| Shares issued for services rendered | 0 |
| Write off of deferred offering costs | 0 |
| Depreciation | 236 |
| Noncash lease expense | 100 |
| Realized gain on sale of marketable securities, net | 119 |
| (accretion) amortization of (discounts) premium on investments, net | -244 |
| (gain) loss on change in fair value of derivative instruments | 1,562 |
| Prepaid expenses and other current assets | 1,042 |
| Operating lease liability | -36 |
| Accrued interest on marketable securities | -168 |
| Accounts payable and accrued expenses | -2,875 |
| Net cash used in operating activities | -17,105 |
| Purchases of property and equipment | 12 |
| Purchase of marketable securities | 44,836 |
| Proceeds from the sale of marketable securities | 2,501 |
| Maturities of marketable securities | 2,500 |
| Net cash (used in) provided by investing activities | -39,847 |
| Proceeds from initial public offering | 327,750 |
| Payment of issuance costs for initial public offering | 24,265 |
| Proceeds from exercise of warrants and options | 247 |
| Proceeds from issuance of redeemable convertible series c preferred stock | 0 |
| Payment of issuance costs for redeemable convertible series c preferred stock | 0 |
| Net cash provided by financing activities | 303,732 |
| Net increase in cash, cash equivalents and restricted cash | 246,780 |
| Cash and cash equivalents at beginning of period | 23,476 |
| Cash and cash equivalents at end of period | 270,256 |
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)